The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

DuPont Delivers Record Full-Year Earnings With 20% Growth in 2011; Posts Fourth Quarter Earnings of $.35 Per Share Ex-Items; Reaffirms 2012 Outlook

Tuesday, January 24, 2012

DuPont Delivers Record Full-Year Earnings With 20% Growth in 2011; Posts Fourth Quarter Earnings of $.35 Per Share Ex-Items; Reaffirms 2012 Outlook06:00 EST Tuesday, January 24, 2012WILMINGTON, Del., Jan. 24, 2012 /PRNewswire/ --Full Year:2011 earnings, before significant items, were up 20 percent to a record $3.93 per share versus $3.28 per share in 2010.  Reported earnings per share were $3.68 versus $3.28 in 2010. Sales of $38.0 billion were up 20 percent, with a 27 percent increase in developing markets. Excluding significant items and Pharmaceuticals, segment pre-tax operating income increased 31 percent with leading contributions from Performance Chemicals and Agriculture. The company generated $3.3 billion free cash flow in 2011 versus $3.1 billion in 2010, driven by increased segment operating income and productivity initiatives. Fixed cost productivity of $400 million and working capital productivity of $500 million significantly exceeded the $300 million targets set for each. For 2012, DuPont reaffirmed its earnings outlook range of $4.20 to $4.40 per share, which represents 7 to 12 percent growth versus 2011, excluding significant items. Fourth Quarter:Fourth quarter 2011 earnings were $.35 per share, excluding significant items, reflecting a $.23 per share year-over-year headwind from a higher tax rate.  Prior year earnings were $.50 per share, excluding significant items.  Reported fourth quarter 2011 earnings were $.40 per share, unchanged from the prior year. Sales grew 14 percent to $8.4 billion, principally from 14 percent higher local prices. A 10 percent net increase from portfolio changes was offset by a 10 percent volume decline.  Agriculture delivered an 8 percent sales gain in the fourth quarter and 23 percent sales growth for the second half. This reflects strong performance during the Latin American selling season.  Excluding significant items and Pharmaceuticals, segment pre-tax operating income increased over $100 million, or 18 percent versus the prior year, principally due to Performance Chemicals and acquisitions in Industrial Biosciences and Nutrition & Health. "We delivered exceptional full-year results in 2011 despite significant market headwinds late in the year," said DuPont Chair and CEO Ellen Kullman.  "Our market-driven science continues to meet customer needs in food, energy and protection.  Acquisitions in Nutrition & Health and Industrial Biosciences, coupled with robust and disciplined productivity efforts across our businesses, contributed to our successful performance. We remain well-positioned to serve customers and innovate as key markets rebound and global population growth drives new opportunities." Global Consolidated Sales and Net IncomeFourth quarter 2011 consolidated net sales of $8.4 billion were 14 percent higher than the prior year.  Volume declines in all regions were driven by destocking in photovoltaics, polymer and industrial supply chains, as well as weaker demand for products supplying consumer electronics and construction. Agriculture volume increased and primarily reflects growth and penetration in the Latin American summer season. The table below shows regional sales and variances versus the fourth quarter 2010.   Three Months Ended December 31, 2011 Percentage Change Due to:(Dollars in billions) $ % Change LocalCurrencyPrice CurrencyEffect Volume Portfolio/OtherU.S. & Canada $     2.7 15 14 - (1) 2EMEA* 2.2 18 11 1 (13) 19Asia Pacific 2.2 7 15 2 (23) 13Latin America 1.3 17 14 (2) (3) 8                          Total Consolidated Sales $     8.4 14 14 - (10) 10                          * Europe, Middle East & Africa          Fourth quarter 2011 net income attributable to DuPont was $373 million versus $376 million in the fourth quarter 2010. Excluding significant items, net income attributable to DuPont was $325 million versus $463 million in the prior year.  The decrease principally reflects a higher tax rate.  Higher selling prices more than offset increased spending for selling, marketing and research and development, higher costs for raw materials, energy and freight, and lower volume. Earnings Per ShareThe table below shows year-over-year earnings per share (EPS) variances for the fourth quarter.    EPS  ANALYSIS      4Q     EPS 2010 $.40    Less: Significant items - (schedule B) (.10)  EPS 2010 ?Excluding significant items .50  Local prices  .98 Variable cost* (.55) Volume  (.20) Fixed cost* (.17) Currency .01     Exchange gains/losses (.04) Income tax (.23) Danisco impact** .04 Other .01     EPS 2011 ? Excluding significant items    $.35     Add: Significant items - (schedule B) .05  EPS 2011 $.40     *     Excludes volume and currency impacts**    Includes interest expense and additional depreciation/amortization expense related to the fairvalue step-up of acquired long-lived Danisco assets        Business Segment Performance - 4th QuarterThe table below shows fourth quarter 2011 segment sales and related variances versus the prior year.SEGMENT SALES*Three Months Ended Percentage Change (Dollars in billions)December 31, 2011Due to: $ % Change USDPrice Volume Portfolio and OtherAgriculture$      1.3 8 5 3 -Electronics & Communications 0.6 (18) 15 (33) -Industrial Biosciences0.3  nm   nm   nm   nm Nutrition & Health0.8 138 3 (3) 138Performance Chemicals1.9 12 29 (17) -Performance Coatings1.1 8 10 (2) -Performance Materials1.6 1 14 (13) -Safety & Protection0.9 10 5 (2) 7 *    Segment sales include transfersSegment pre-tax operating income (PTOI), excluding significant items, increased 16 percent to $763 million largely driven by improvements in Performance Chemicals and Agriculture, and acquisitions in Nutrition & Health and Industrial Biosciences, as shown in the table below.SEGMENT PTOI excluding Significant Items*   Change versus 2010(Dollars in millions) 4Q 2011 4Q 2010 $ %         Agriculture$(116) $   (135) $      19 nmElectronics & Communications$42 98 (56) -57%Industrial Biosciences$34 - 34 nmNutrition & Health$52 18 34 189%Performance Chemicals$433 315 118 37%Performance Coatings$58 71 (13) -18%Performance Materials$151 206 (55) -27%Safety & Protection$94 92 2 2%Other** (74) (95) 21 nm $674 $     570 $     104 18%Pharmaceuticals 89 87 2 2%Total Segment PTOI$763 $     657 $     106 16%         * See Schedules B and C for listing of significant items and their impact by segment. **4Q 2010 includes $32 million in charges related to legal settlements for discontinued businesses. Business Segment Performance - Full YearThe tables below show full-year 2011 segment sales with related variances versus the prior year, and full-year PTOI excluding significant items. 12 Months Ended Percentage Change SEGMENT SALES*December 31, 2011Due to:(Dollars in billions)          $ % Change USDPrice Volume Portfolio and OtherAgriculture9.2 17 6 10 1Electronics & Communications 3.2 15 23 (8) -Industrial Biosciences0.7  nm   nm   nm   nm Nutrition & Health2.5 98 5 1 92Performance Chemicals7.8 23 26 (3) -Performance Coatings4.3 12 10 2 -Performance Materials6.8 8 13 (4) (1)Safety & Protection3.9 17 6 4 7 *    Segment sales include transfersSEGMENT PTOI excluding Significant Items*      (Dollars in millions)     Change versus 2010  FY 2011 FY 2010 $ %         Agriculture $  1,752 $   1,343 $      409 30%Electronics & Communications 355 437 (82) -19%Industrial Biosciences 78 - 78 nmNutrition & Health 170 62 108 174%Performance Chemicals 1,923 1,071 852 80%Performance Coatings 268 255 13 5%Performance Materials 924 978 (54) -6%Safety & Protection 500 449 51 11%Other (235) (206) (29) nm  $  5,735 $   4,389 $    1,346 31%Pharmaceuticals 289 489 (200) -41%Total Segment PTOI $  6,024 $   4,878 $    1,146 23%         * See Schedules B and C for listing of significant items and their impact by segment.The following is a summary of business results for each of the company's reportable segments, comparing fourth quarter 2011 with fourth quarter 2010, for sales and PTOI (loss) excluding significant items. References to selling price are on a U.S. dollar basis, including the impact of currency.Agriculture - Sales of $1.3 billion were up 8 percent, with 5 percent higher selling prices and 3 percent higher volume.  PTOI seasonal loss of $(116) million improved $19 million due to higher sales.  Full-year sales of $9.2 billion grew 17 percent with 10 percent volume gains, 6 percent higher prices and 1 percent impact from portfolio changes.  Full-year PTOI grew 30 percent with 19 percent PTOI margins. In seeds, sales reflected success in each region with volume and price gains. In crop protection, sales growth was delivered in each product line and region.Electronics & Communications - Sales of $630 million were down 18 percent reflecting 33 percent lower volume partially offset by 15 percent higher selling prices related to pass-through of metal prices.  Lower volume reflects destocking in photovoltaics and softness in consumer electronics.  PTOI of $42 million decreased on lower volume, partially offset by OLED technology licensing income of $20 million.Industrial Biosciences - Sales of $289 million and PTOI of $34 million reflect the acquisition of Danisco's enzyme business.  PTOI includes $6 million of amortization expense associated with the fair value step-up of acquired intangible assets. Nutrition & Health - Sales of $806 million were up $468 million from the acquisition of Danisco's specialty food ingredients business.  PTOI of $52 million reflects the acquisition and favorable product mix in Solae.  PTOI includes $20 million of amortization expense associated with the fair value step-up of acquired intangible assets.Performance Chemicals - Sales of $1.9 billion were up 12 percent, with 29 percent higher selling prices and 17 percent lower volume.  Higher selling prices reflect pricing actions to offset higher raw material costs.  Lower volume was attributable to a pause in demand for titanium dioxide, particularly in Asia Pacific.  PTOI of $433 million increased $118 million on higher selling prices.Performance Coatings - Sales of $1.1 billion were up 8 percent, with 10 percent higher selling prices and 2 percent lower volume.  Higher selling prices reflect pricing actions across all market segments to offset higher raw material costs.  Lower volume resulted from destocking and flat/lower builds in all regions except North America.  Demand continued to be strong in the North American OEM motor vehicle and heavy duty truck markets.  PTOI of $58 million decreased on weaker mix and a $7 million settlement.Performance Materials - Sales of $1.6 billion were up 1 percent, with 14 percent higher selling prices and 13 percent lower volume. Higher selling prices offset higher raw material costs.  Lower volume reflects broad-based channel destocking along with softening in consumer and industrial markets.  PTOI of $151 million decreased due to lower volume and the absence of a prior year $31 million combined benefit from an acquisition and an early termination of a supply agreement.Safety & Protection - Sales of $943 million were up 10 percent, with a 7 percent increase from the MECS acquisition and 5 percent higher selling prices, partially offset by 2 percent lower volume.  Higher selling prices more than offset raw material cost increases.  Volume was lower on destocking in the industrial markets.  PTOI of $94 million was essentially flat.  Prior year included a net $11 million charge related to an asset impairment and a separate gain on an asset sale.  Additional information is available on the DuPont Investor Center website at www.dupont.com.Outlook  DuPont reaffirms its full-year 2012 earnings outlook of $4.20 to $4.40 per share, an increase of 7 to 12 percent versus 2011, excluding significant items.  Use of Non-GAAP MeasuresManagement believes that certain non-GAAP measurements are meaningful to investors because they provide insight with respect to ongoing operating results of the company.  Such measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance.  Reconciliations of non-GAAP measures to GAAP are provided in schedules C and D.DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802.  The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment.  For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.Forward-Looking Statements:  This news release contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates" or other words of similar meaning.  All statements that address expectations or projections about the future, including statements about the company's growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements.  Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized.  Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control.  Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; inability to protect and enforce the company's intellectual property rights; and integration of acquired businesses and completion of divestitures of underperforming or non-strategic assets or businesses.  The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.E. I. du Pont de Nemours and CompanyConsolidated Income Statements(Dollars in millions, except per share amounts)SCHEDULE A        Three Months EndedDecember 31, Year EndedDecember 31, 2011 2010 2011 2010Net sales$           8,425 $            7,404 $         37,961 $          31,505Other income, net(a)343 338 758 1,228Total8,768 7,742 38,719 32,733        Cost of goods sold and other operating charges (a)6,685 5,923 27,814 23,146Selling, general and administrative expenses993 873 4,170 3,669Research and development expense (a)538 473 1,956 1,651Interest expense (a)116 281 447 590Employee separation / asset related charges, net (a)14 (34) 50 (34)Total8,346 7,516 34,437 29,022        Income before income taxes422 226 4,282 3,711Provision for (benefit from) income taxes (a)45 (152) 772 659        Net income 377 378 3,510 3,052        Less:  Net income attributable to noncontrolling interests4 2 36 21        Net income attributable to DuPont$              373 $               376 $           3,474 $            3,031        Basic earnings per share of common stock$             0.40 $              0.41 $             3.73 $              3.32        Diluted earnings per share of common stock $             0.40 $              0.40 $             3.68 $              3.28        Dividends per share of common stock$             0.41 $              0.41 $             1.64 $              1.64        Average number of shares outstanding used in earningsper share (EPS) calculation:         Basic925,588,000 914,403,000 928,417,000 908,860,000  Diluted935,709,000 928,800,000 941,029,000 921,655,000                (a) See Schedule B for detail of significant items.               E. I. du Pont de Nemours and CompanyCondensed Consolidated Balance Sheets(Dollars in millions, except per share amounts)SCHEDULE A (continued)     December 31, 2011 December 31, 2010 Assets    Current assets    Cash and cash equivalents$           3,586 $           4,263 Marketable securities433 2,538 Accounts and notes receivable, net 6,022 5,635 Inventories 7,195 5,967 Prepaid expenses 151 122 Deferred income taxes 671 534 Total current assets18,058 19,059 Property, plant and equipment, net of accumulated depreciation    (December 31, 2011 - $19,349; December 31, 2010 - $18,628)13,412 11,339 Goodwill5,413 2,617 Other intangible assets 5,413 2,704 Investment in affiliates1,117 1,041 Deferred income taxes 4,067 2,772 Other assets 1,012 878 Total$         48,492 $         40,410      Liabilities and Stockholders' Equity    Current liabilities    Accounts payable$           4,816 $           4,349 Short-term borrowings and capital lease obligations 817 133 Income taxes 255 225 Other accrued liabilities 5,297 4,682 Total current liabilities11,185 9,389 Long-term borrowings and capital lease obligations 11,736 10,137 Other liabilities 15,508 11,026 Deferred income taxes 1,001 115 Total liabilities39,430 30,667      Commitments and contingent liabilities          Stockholders' equity    Preferred stock237 237 Common stock, $0.30 par value; 1,800,000,000 shares authorized;    issued at December 31, 2011 - 1,013,164,000; December 31, 2010 - 1,004,351,000304 301 Additional paid-in capital10,107 9,227 Reinvested earnings13,422 12,030 Accumulated other comprehensive loss (8,750) (5,790) Common stock held in treasury, at cost (87,041,000 shares    at December 31, 2011 and December 31, 2010)(6,727) (6,727) Total DuPont stockholders' equity8,593 9,278 Noncontrolling interests469 465 Total equity9,062 9,743 Total$         48,492 $         40,410      E. I. du Pont de Nemours and CompanyCondensed Consolidated Statement of Cash Flows(Dollars in millions)SCHEDULE A (continued)    Year EndedDecember 31, 2011 2010    Cash provided by (used for) operating activities$          5,152 $          4,559    Investing activities   Purchases of property, plant and equipment(1,843) (1,508)Investments in affiliates(67) (100)Payments for businesses (net of cash acquired)(6,459) (637)Net (increase) decrease in short-term financial instruments2,149 (457)Other investing activities - net(18) 263Cash provided by (used for) investing activities(6,238) (2,439)    Financing activities   Dividends paid to stockholders(1,533) (1,501)Net increase (decrease) in borrowings1,561 (778)Repurchase of common stock(672) (250)Proceeds from exercise of stock options952 708Other financing activities - net95 (8)Cash provided by (used for) financing activities403 (1,829)    Effect of exchange rate changes on cash6 (49)    Increase (decrease) in cash and cash equivalents(677) 242    Cash and cash equivalents at beginning of period4,263 4,021    Cash and cash equivalents at end of period$          3,586 $          4,263    E. I. du Pont de Nemours and Company Schedule of Significant Items (Dollars in millions, except per share amounts)SCHEDULE B SIGNIFICANT ITEMS             Pre-tax After-tax ($ Per Share)  2011 2010 2011 2010 2011 20101st Quarter - Total$              - $              - $              - $              - $              - $              -2nd Quarter            Transaction costs related to Danisco (a)$        (103) $              - $          (81) $              - $       (0.08) $              - Adjustments related to income tax settlements (b)- 59 - 87 - 0.092nd Quarter - Total$        (103) $            59 $          (81) $            87 $       (0.08) $         0.093rd Quarter            Transaction costs and restructuring charge               related to Danisco (c)$       (171) $               - $       (122) $               - $      (0.13) $              - Customer claims charge (d)(75) - (48) - (0.05) - Milestone payment for licensing agreement (e)(50) - (33) - (0.03) -3rd Quarter - Total$        (296) $              - $        (203) $              - $       (0.21) $              -4th Quarter            Customer claims charge (d)$        (100) $              - $          (64) $              - $       (0.07) $              - Sale of a business (f)49 - 122 - 0.13 - Restructuring charge / adjustments (g)(14) 34 (10) 23 (0.01) 0.02 Charge related to early extinguishment of debt (h)- (179) - (117) - (0.13) Upfront payment for licensing agreement (e)- (50) - (32) - (0.03) Reversal of tax valuation allowances (i)- - - 39 - 0.044th Quarter - Total$          (65) $        (195) $            48 $          (87) $         0.05 $       (0.10)             Full Year - Total(j)$        (464) $        (136) $        (236) $              - $       (0.25) $              -                          (a)Second quarter 2011 included charges related to the Danisco acquisition of $(103) recorded in Cost of goods sold and other operating charges.  These charges included $(60) of transaction costs and a $(43) charge related to the fair value step-up of inventories that were acquired from Danisco and sold in the second quarter 2011. Pre-tax charges by segment were: Industrial Biosciences - $(17), Nutrition & Health - $(33), and Corporate expenses - $(53).(b)Second quarter 2010 included benefits for the adjustment of accrued interest of $59 ($38 after-tax) recorded in Other income, net and the adjustment of income tax accruals of $49 associated with settlements of tax contingencies related to prior years.(c)Third quarter 2011 included charges related to the Danisco acquisition of $(171).  These charges included $(135) recorded in Cost of goods sold and other operating charges for $(3) of transaction costs and a $(132) charge related to the fair value step-up of inventories that were acquired from Danisco and sold in the third quarter 2011.  These charges also included a $(36) restructuring charge recorded in Employee separation / asset related charges, net related to severance and related benefit costs.  Pre-tax charges by segment were: Industrial Biosciences - $(61), Nutrition & Health - $(89), Other - $(18), and Corporate expenses - $(3).(d)Third quarter and fourth quarter 2011 included charges of $(75) and $(100), respectively, recorded in Cost of goods sold and other operating charges associated with the company's process to fairly resolve claims associated with the use of Imprelis® herbicide.  The company will continue to evaluate reported claim damage as additional information becomes available, which could result in future charges that cannot be reasonably estimated at this time; the company intends to seek recovery from its insurance carriers for costs associated with this matter in excess of $100.  This matter relates to the Agriculture segment.(e)Third quarter 2011 and fourth quarter 2010 each included a $(50) charge recorded in Research and development expense in connection with payments associated with a Pioneer licensing agreement. (f)Fourth quarter 2011 included a pre-tax gain of $49 recorded in Other income, net associated with the sale of a business in the Performance Materials segment and a related tax benefit of $73.(g)Fourth quarter 2011 included a $(14) restructuring charge recorded in Employee separation / asset related charges, net primarily related to severance and related benefit costs associated with the Danisco acquisition, partially offset by a reversal of prior year restructuring accruals.  Pre-tax charges by segment were: Industrial Biosciences - $(1), Nutrition & Health - $(4), Performance Coatings - $3, Performance Materials - $(2) , and Other - $(10). Fourth quarter 2010 included a net reduction of $34 for estimated costs recorded in Employee separation / asset related charges, net related to the 2008 and 2009 restructuring programs primarily due to the achievement of work force reductions through non-severance programs.  Total pre-tax amounts by segment were: Electronics and Communications - $8, Performance Chemicals - $10, Performance Coatings - $(6), Performance Materials - $16, Safety & Protection - $5, and Other - $1.(h)Fourth quarter 2010 included a $(179) charge recorded in Interest expense associated with the early extinguishment of debt.(i)Fourth quarter 2010 included a $39 benefit for the reversal of a tax valuation allowance related to the net deferred tax assets of a foreign subsidiary.(j)Earnings per share for the year do not equal the sum of quarterly earnings per share due to changes in average share calculations.             See Schedule C for detail by segment.             E. I. du Pont de Nemours and Company Consolidated Segment Information (Dollars in millions)SCHEDULE C        Three Months EndedDecember 31, Year EndedDecember 31,SEGMENT SALES (1)2011 2010 2011 2010Agriculture$    1,297 $    1,204 $    9,166 $    7,845Electronics & Communications630 773 3,173 2,764Industrial Biosciences289 - 705 -Nutrition & Health806 338 2,460 1,240Performance Chemicals1,860 1,664 7,794 6,322Performance Coatings1,083 1,005 4,281 3,806Performance Materials1,618 1,599 6,815 6,287Safety & Protection943 859 3,934 3,364Other1 40 40 194Total Segment sales8,527 7,482 38,368 31,822        Elimination of transfers(102) (78) (407) (317)Consolidated net sales$    8,425 $    7,404 $  37,961 $  31,505                (1)   Sales for the reporting segments include transfers.               E. I. du Pont de Nemours and Company Consolidated Segment Information (Dollars in millions)SCHEDULE C (continued)          Three Months EndedDecember 31, Year EndedDecember 31,PRE-TAX OPERATING INCOME/(LOSS) (PTOI) 2011 2010 2011 2010Agriculture  $     (216) $    (185) $    1,527 $   1,293Electronics & Communications 42 106 355 445Industrial Biosciences 33 - (1) -Nutrition & Health 48 18 44 62Performance Chemicals 433 325 1,923 1,081Performance Coatings 61 65 271 249Performance Materials 198 222 971 994Safety & Protection 94 97 500 454Pharmaceuticals  89 87 289 489Other (84) (94) (263) (205)Total Segment PTOI 698 641 5,616 4,862         Net exchange gains (losses) (1) (18) 12 (163) (13)Corporate expenses & net interest (258) (427) (1,171) (1,138)Income before income taxes $       422 $      226 $    4,282 $   3,711                    Three Months EndedDecember 31, Year EndedDecember 31,SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX) (2) 2011 2010 2011 2010Agriculture  $     (100) $      (50) $     (225) $      (50)Electronics & Communications - 8 - 8Industrial Biosciences (1) - (79) -Nutrition & Health (4) - (126) -Performance Chemicals - 10 - 10Performance Coatings 3 (6) 3 (6)Performance Materials 47 16 47 16Safety & Protection - 5 - 5Pharmaceuticals  - - - -Other (10) 1 (28) 1Total significant items by segment $       (65) $      (16) $     (408) $      (16)                    Three Months EndedDecember 31, Year EndedDecember 31,PTOI EXCLUDING SIGNIFICANT ITEMS 2011 2010 2011 2010Agriculture  $     (116) $    (135) $    1,752 $   1,343Electronics & Communications 42 98 355 437Industrial Biosciences 34 - 78 -Nutrition & Health 52 18 170 62Performance Chemicals 433 315 1,923 1,071Performance Coatings 58 71 268 255Performance Materials 151 206 924 978Safety & Protection 94 92 500 449Pharmaceuticals  89 87 289 489Other (74) (95) (235) (206)Total Segment PTOI excluding significant items $       763 $      657 $    6,024 $   4,878         (1)  See Schedule D for additional information on exchange gains and losses.(2)  See Schedule B for detail of significant items.    E. I. du Pont de Nemours and CompanyReconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)SCHEDULE D Summary of Earnings Comparisons             Three Months Ended December 31,  Year EndedDecember 31,  2011 2010 % Change 2011 2010 % Change            Segment PTOI$                 698 $               641 9% $            5,616 $           4,862 16%Significant items (benefit) charge included in PTOI (per Schedule C)65 16   408 16  Segment PTOI excluding significant items$                 763 $               657 16% $            6,024 $           4,878 23%            Net income attributable to DuPont$                 373 $               376 -1% $            3,474 $           3,031 15%Significant items (benefit) charge included in net income           attributable to DuPont (per Schedule B)(48) 87   236 -  Net income attributable to DuPont           excluding significant items$                 325 $               463 -30% $            3,710 $           3,031 22%            EPS$                0.40 $              0.40 0% $              3.68 $             3.28 12%Significant items (benefit) charge included in EPS (per Schedule B)(0.05) 0.10   0.25 -  EPS excluding significant items$                0.35 $              0.50 -30% $              3.93 $             3.28 20%            Average number of diluted shares outstanding935,709,000 928,800,000 0.7% 941,029,000 921,655,000 2.1%  E. I. du Pont de Nemours and CompanyReconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)SCHEDULE D (continued)         Reconciliations of Adjusted EBIT / EBITDA to Consolidated Income Statements          Three Months EndedDecember 31, Year EndedDecember 31,  2011 2010 2011 2010          Income before income taxes$             422 $             226 $          4,282 $          3,711 Less: Net income attributable to noncontrolling interests4 2 36 21 Add:  Interest expense 116 281 447 590 Adjusted EBIT534 505 4,693 4,280 Add: Depreciation and amortization 421 334 1,560 1,380 Adjusted EBITDA$             955 $             839 $          6,253 $          5,660                            Calculation of Free Cash Flow          Year EndedDecember 31,            2011 2010     Cash provided by (used for) operating activities$          5,152 $          4,559     Less: Purchases of property, plant and equipment1,843 1,508     Free cash flow$          3,309 $          3,051                                Reconciliations of Fixed Costs as a Percent of Sales          Three Months EndedDecember 31, Year EndedDecember 31,  2011 2010 2011 2010          Total charges and expenses - consolidated income statements$          8,346 $          7,516 $        34,437 $        29,022 Remove:             Interest expense(116) (281) (447) (590)    Variable costs (1)(4,172) (3,734) (18,377) (15,329)    Significant items - benefit (charge) (2)(114) (16) (513) (16)        Fixed costs$          3,944 $          3,485 $        15,100 $        13,087          Consolidated net sales$          8,425 $          7,404 $        37,961 $        31,505          Fixed costs as a percent of consolidated net sales46.8% 47.1% 39.8% 41.5%          (1)  Includes variable manufacturing costs, freight, commissions and other selling expenses which vary with the volume of sales. (2)  See Schedule B for detail of significant items.     E. I. du Pont de Nemours and CompanyReconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)SCHEDULE D (continued) Exchange Gains/(Losses)The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes. The net pre-tax exchange gains and losses are recorded in Other income, net and the related tax impact is recorded in Provision for (benefit from) income taxes on the Consolidated Income Statements.           Three Months EndedDecember 31, Year Ended December 31,  2011 2010 2011 2010Subsidiary/Affiliate Monetary Position Gain (Loss)        Pre-tax exchange gains (losses) (includes equity affiliates) $       (87) $          (5) $       (30) $      (130)Local tax benefits (expenses) 5 (11) 36 (30)Net after-tax impact from subsidiary exchange gains (losses) $       (82) $        (16) $           6 $      (160)         Hedging Program Gain (Loss)        Pre-tax exchange gains (losses) $         69 $          17 $     (133) $        117Tax benefits (expenses) (24) (6) 46 (41)Net after-tax impact from hedging program exchange gains (losses) $         45 $          11 $       (87) $          76         Total Exchange Gain (Loss)        Pre-tax exchange gains (losses) $       (18) $          12 $     (163) $        (13)Tax benefits (expenses) (19) (17) 82 (71)Net after-tax exchange gains (losses) $       (37) $          (5) $       (81) $        (84)         As shown above, the "Total Exchange Gain (Loss)" is the sum of the "Subsidiary/Affiliate Monetary Position Gain (Loss)" and the "Hedging Program Gain (Loss)."                             Reconciliation of Base Income Tax Rate to Effective Income Tax Rate    Base income tax rate is defined as the effective income tax rate less the effect of exchange gains/losses, as defined above, and significant items.            Three Months EndedDecember 31, Year Ended December 31,  2011 2010 2011 2010         Income before income taxes  $       422 $        226 $    4,282 $     3,711Add:  Significant items - (benefit) charge (1) 65 195 464 136Less:  Net exchange gains (losses) (18) 12 (163) (13)Income before income taxes, significant items and exchange gains/losses $       505 $        409 $    4,909 $     3,860         Provision for (benefit from) income taxes $         45 $      (152) $       772 $        659Add:  Tax benefits (expenses) on significant items 113 108 228 136          Tax benefits (expenses) on exchange gains/losses (19) (17) 82 (71)Provision for income taxes, excluding taxes on significant items    and exchange gains/losses $       139 $        (61) $    1,082 $        724         Effective income tax rate 10.7% (67.3)% 18.0% 17.8%Significant items effect 21.7% 56.9% 3.1% 2.9%Tax rate before significant items 32.4% (10.4)% 21.1% 20.7%Exchange gains (losses) effect (4.9)% (4.5)% 0.9% (1.9)%Base income tax rate 27.5% (14.9)% 22.0% 18.8%                  (1)  See Schedule B for detail of significant items.          SOURCE DuPontFor further information: CONTACT: Media Contact: Michael Hanretta, +1-302-774-4005, michael.j.hanretta@usa.dupont.com; Investor Contact: +1-302-774-4994